Acquired haemophilia and its management (Q40602765)

21 September 2017

1 reference

title

Acquired haemophilia and its management (English)

1 reference

21 September 2017

0 references

0 references

Morrison AE

1 reference

21 September 2017

Ludlam CA

series ordinal

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 February 1995

1 reference

British Journal of Haematology

21 September 2017

published in

1 reference

21 September 2017

1 reference

21 September 2017

1 reference

21 September 2017

page(s)

231-236

1 reference

Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

The mode of action of antibodies which destroy factor VIII. II. Antibodies which give complex concentration graphs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Haemophilia due to factor VIII inhibitors in a patient suffering from an autoimmune disease: treatment with intravenous immunoglobulin. A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Efficacy of porcine factor VIII in the management of haemophiliacs with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

An acquired inhibitor to factor VIIIC in a non-hemophiliac: twenty years of observation and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Assay and characterization of the factor in porcine and bovine plasma which aggregates human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Immunochemistry of factor VIII:C inhibitor antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

A circulating anticoagulant in gamma-1A-multiple myeloma: its modification by penicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Cytotoxic suppression of acquired factor VIII:C inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Failure of high-dose i.v. gammaglobulin in the treatment of spontaneously acquired factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

The use of polyelectrolyte-fractionated porcine factor VIII in the treatment of a spontaneously acquired inhibitor to factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

The Relevance of Factor VIII Inactivation Characteristics in the Treatment of Patients with Antibodies Directed against Factor VIII

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Rationale and evolution of therapy with porcine factor VIII:C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Activated prothrombin concentrate for patients with factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Cyclosporin treatment of a woman with acquired haemophilia due to factor VIII:C inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

The Treatment of Patients who have Factor-VIII Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Effect of commercial immunoglobulin G preparation on human monocyte Fc-receptor dependent binding of antibody coated platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

The immunologic character of acquired inhibitors of antihemophilic globulin (factor 8) and the kinetics of their interaction with factor 8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Disseminated intravascular coagulation and infusion of factor-VIII-inhibitor bypassing activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

The rapid development of an IgM inhibitor of porcine factor VIII in a patient with acquired haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03294.X

10.1111/J.1365-2141.1995.TB03294.X

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference